NCT05758688 2026-03-12
PROPS GYN
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
Clinical Trials
5 trialsNCT06369155 2026-03-02
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT06677190 2025-11-05
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05916196 2025-05-08
[18F]FES PET/.CT in Uterine Cancer
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT06180733 2023-12-22
PAM-II
University Medical Center Groningen
Phase 2 Recruiting